Author(s): Fishman A, Friedman JA, Kaplan AL
Abstract Share this page
Abstract Oral contraceptives have been reported to confer protective effect against tendometrial and ovarian carcinoma. An uncommon presentation of concomitant endometrial and ovarian cancer in a young patient using oral contraception is reported. PIP: Use of combined oral contraceptives (OCs) has been associated, in numerous studies, with a duration-linked protective effect against ovarian and endometrial cancers. Reported in this paper is the case of a 28-year-old US OC user with concomitant carcinomas of the cervix and endometrium. The woman had been taking combined OCs for 4 years when she presented for intermittent mid-cycle bleeding of about 9 month's duration. The pelvic examination showed a normal size uterus slightly irregular in contour; the Pap smear was normal. The patient did not return for the recommended dilatation and curettage until 6 months later, when her symptoms persisted. At that time, laparoscopy revealed bilateral ovarian enlargement. Frozen section biopsies identified adenocarcinoma in both ovaries and the uterus. Total abdominal hysterectomy, bilateral salpingo-ophorectomy, omenectomy, and complete cervical staging were performed. The lesion in the left ovary was considered to represent a metastasis from the endometrial primary, while the lesion in the right ovary was viewed as a separate primary. Although synchronous primary cancer of the endometrium and ovary is a rare event, the women affected tend to be premenopausal with a median age of 41 years.
This article was published in Eur J Gynaecol Oncol
and referenced in Journal of Addiction Research & Therapy